ProKidney's Major Step in Chronic Kidney Disease Treatment Announced

Author: Ryan Hughes Updated: 10-20-2025 07:37 AM

ProKidney Presents Groundbreaking Research at ASN Kidney Week 2025

In a significant development for chronic kidney disease (CKD) treatment, ProKidney Corp. (Nasdaq: PROK) proudly announces the selection of two vital abstracts for presentation at the esteemed American Society of Nephrology’s (ASN) Kidney Week 2025. Set to take place from November 6 to 9 in Houston, Texas, this event underscores the company’s commitment to advancing therapeutic options for patients suffering from CKD.

Key Presentations to Highlight Innovative Research

The abstracts accepted for this year’s Kidney Week showcase exciting advancements in ProKidney's research portfolio. The anticipation surrounds the late-breaking poster that details the results of the Phase 2 REGEN-007 study.

Presentation Details of the Late-Breaking Study

The study titled Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results) will be featured during a dedicated session for late-breaking science posters from 10:00 AM to 12:00 PM CST. Attendees can find this groundbreaking research on Poster Board #: TH-PO1203.

Exploring Inflammatory Profiles with the Other Presentation

Additionally, ProKidney will present another poster titled Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel. This presentation is scheduled for the same day and time as the late-breaking session, positioned on Poster Board #: TH-PO0575. This presentation is expected to contribute valuable insights regarding the inflammatory profiles associated with ProKidney's therapeutic candidates.

Post-Event Availability and Access

For those unable to attend the event, fear not! ProKidney will make the poster presentations available on the company’s official website following the conference. This will provide an opportunity to explore the groundbreaking findings in detail and understand more about the promising advancements in CKD therapies.

About ProKidney and Its Innovations

Founded in 2015, ProKidney is dedicated to transforming CKD treatment through innovative cellular therapy solutions. The company’s lead product candidate, rilparencel (also known as REACT), represents a revolutionary approach in regenerative medicine with a patented, proprietary design. Currently, rilparencel is being studied in the ongoing Phase 3 REGEN-006 (PROACT 1) study, which aims to evaluate its effectiveness in preserving kidney function among patients with advanced CKD and type 2 diabetes.

Contact ProKidney for More Information

For further inquiries about ProKidney’s advancements or research, interested parties can reach out to:

Frequently Asked Questions

What is ProKidney Corp. known for?

ProKidney Corp. specializes in developing innovative cellular therapies aimed at treating chronic kidney disease.

When is ASN Kidney Week 2025?

ASN Kidney Week 2025 will occur from November 6 to 9 in Houston, Texas.

What are the titles of the presentations by ProKidney?

ProKidney will present two abstracts: one on renal autologous cell therapy and another on inflammatory profile characterization related to its cell therapy candidate rilparencel.

Will the poster presentations be available after ASN Kidney Week?

Yes, ProKidney will make the poster presentations available on its official website following the event.

How can I contact ProKidney for more information?

You can contact ProKidney via email through the provided contacts for any inquiries or information regarding their research and innovations.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.